Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Growth Hormone Deficiency – Executive Insights – Growth hormone deficiency: Executive Insights (US)

Login to access report north_east
Contact sales account_box

Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often cumbersome. Recombinant human growth hormone (rhGH) has been the mainstay treatment for GHD since 1985. The current landscape for rhGH therapy is very competitive; several products are approved, and only a few agents are in late-phase clinical trials. Each of the products in development aims to improve the frequency of dosing, thereby reducing the burden on patients.

Questions answered

  • What is the prevalence of GHD? How are U.S. GHD patients managed?
  • What are the key areas of unmet need and opportunities in the treatment of GHD?
  • Which therapies are in late-phase development for GHD? What is the potential impact of new launches, and how will these therapies affect future opportunity in the treatment of GHD?
  • What are the key drivers of, and limitations on, the market today and in the future?

Product description

Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Geography: United States

Primary research: Three KOL interviews from March 2023

Key companies covered: Novo Nordisk, Eli Lilly, Roche / Genentech, Pfizer, Sandoz, Merck KGaA, Ferring, Ascendis Pharma, Lumos Pharma

Key drugs covered: Norditropin, Genotropin / Genotropin MiniQuick, Omnitrope, Humatrope, Nutropin, Saizen, Zomacton, Skytrofa, Somapacitan (Sogroya), Somatrogon (Ngenla), Ibutamoren mesylate (LUM 201)

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east